» Articles » PMID: 30848198

MicroRNAs As Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma

Overview
Specialty Pharmacology
Date 2019 Mar 9
PMID 30848198
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a common cancer, and the second most common cause of cancer-associated death globally. One of the major reasons for this high rate of mortality is a failure to make an early diagnosis. The average survival in untreated HCC patients is estimated to be approximately three months. The 5-year overall survival rate after radical resection is about 15-40% and within two years, more than two third of patients experience a relapse. To date, the most common biomarker which has been used for the diagnosis of HCC is serum alpha-fetoprotein (AFP). However, there is a lack of sensitive and specific tumor biomarkers for the early diagnosis of HCC. MicroRNAs are a class of short endogenous RNA with crucial role in many biological activities and cellular pathways and can be found in various tissues and body fluids. The aim of this review was to summarize the results of recent studies investigating miRNAs as novel biomarkers for the early diagnosis and prognostic risk stratification of patients with this type of liver cancer.

Citing Articles

Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.

Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E Heliyon. 2024; 10(20):e39489.

PMID: 39498055 PMC: 11532857. DOI: 10.1016/j.heliyon.2024.e39489.


The preliminary data of gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in the Turkish population in HBV-related hepatocellular carcinoma.

Kadioglu D, Demirtas C, Pirim D, Dilber F, Eren F Hepatol Forum. 2024; 5(3):106-112.

PMID: 39006138 PMC: 11237244. DOI: 10.14744/hf.2023.2023.0054.


Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease.

Michalczuk M, Longo L, Keingeski M, de Souza Basso B, Guerreiro G, Ferrari J World J Hepatol. 2024; 16(1):75-90.

PMID: 38313241 PMC: 10835481. DOI: 10.4254/wjh.v16.i1.75.


Research progress of circulating non-coding RNA in diagnosis and treatment of hepatocellular carcinoma.

You J, Xia H, Huang Z, He R, Zhao X, Chen J Front Oncol. 2023; 13:1204715.

PMID: 37546394 PMC: 10400719. DOI: 10.3389/fonc.2023.1204715.


LncRNA HULC and miR-122 Expression Pattern in HCC-Related HCV Egyptian Patients.

Gaber D, Shaker O, Younis A, El-Kassas M Genes (Basel). 2022; 13(9).

PMID: 36140836 PMC: 9498747. DOI: 10.3390/genes13091669.